Janet Carlson’s Post

Are you attending the World Orphan Drug Congress April 23 - 25th in Boston? If you haven't made a decision yet, here are 3 reasons to attend: 1. #1 Networking opportunity in the rare disease and orphan drug space: The event brings together key stakeholders from across the orphan drug ecosystem, including pharmaceutical companies, biotechs, patient advocacy groups, regulatory agencies, and investors. Networking at the event provides attendees with the chance to forge valuable connections, collaborate on projects, and explore potential partnerships that can drive innovation and advance research in orphan drug development. 2. Access to Industry Insights and Expertise: The event features 3-days of insightful and inspiring presentations, keynote sessions, workshops, roundtables, and so much more led by leading experts and thought leaders in the field of rare diseases and orphan drugs. 3. Learning and Education: whether you’re a researcher clinician, industry executive, or policymaker, WODC will enhance your knowledge base, deepen your understanding of rare diseases, and keep you up to date on the latest advances in orphan drug development and patient care. And if you need another reason, I'll be there and I'd love to connect with you! If you are planning to attend, leave me a comment and let's connect!! #raredisease #rarediseases #rareaccessactionproject #WODC #smallbiopharma

Are you attending the World Orphan Drug Congress April 23 - 25, 2024 in Boston? If you need reasons to attend, here are 3 great reasons: 1. #1 Networking opportunity in the rare disease and orphan drug space: The event brings together key stakeholders from across the orphan drug ecosystem, including pharmaceutical companies, biotechs, patient advocacy groups, regulatory agencies, and investors. Networking at the event provides attendees with the chance to forge valuable connections, collaborate on projects, and explore potential partnerships that can drive innovation and advance research in orphan drug development. 2. Access to Industry Insights and Expertise: The event features 3-days of insightful and inspiring presentations, keynote sessions, workshops, roundtables, and so much more led by leading experts and thought leaders in the field of rare diseases and orphan drugs. 3. Learning and Education: whether you’re a researcher clinician, industry executive, or policymaker, WODC will enhance your knowledge base, deepen your understanding of rare diseases, and keep you up to date on the latest advances in orphan drug development and patient care. And if you need another reason, I’ll be there!! If you are attending, leave me a comment - I am looking to meet people! #raredisease #rarediseases #rareaccessactionproject #WODC #smallbiopharma

🔍 What’s stopping pharma companies from running commercial trials in Africa? We agree it's the right and ethical thing to do, yet it isn't happening... No one wants to be the first. eMQT proposes a change! 🌍 Calling all pharma companies committed to diversity in clinical trials. Join us in building Centres of Excellence together! 🌟 Here’s our simple 3-step proposal: 1️⃣ Meet with eMQT to discuss your therapeutic area and patient population focus. 2️⃣ We identify suitable sites and countries in Africa to match your needs. 3️⃣ Collaborate with us to build Centres of Excellence! Let’s lead the way in transforming clinical research.💡🤝 #DiversityInTrials #ClinicalResearch #PharmaInnovation Contact us today to start the journey! 🌟 https://buff.ly/40eOKUb Pfizer Roche AstraZeneca Gilead Sciences Vertex Pharmaceuticals Veramed Takeda GSK Genentech Novartis Moderna Shalom Ijeoma Lloyd MBE Tina Barton Emily Moore Hannah White Nancy Meyerson-Hess

We are thrilled to announce the continued collaboration between Astellas and Patient Advocacy Leaders and Drug Development Industry Network (PALADIN), as well as the launch of the highly anticipated PALADIN Playbook and Resource Repository. This collaboration represents an important milestone in our efforts to advance patient advocacy group (PAG) and industry collaborations, with the ultimate goal of increasing access to life-saving treatments. PALADIN Consortium, in which Astellas is an active participant, plays a pivotal role in establishing more effective relationships between PAGs and biopharmaceutical companies. By developing consensus-based guidelines, training, resources, and competencies, PALADIN aims to optimize collaborations and transform the pace of new medical therapies' development. We are excited about the potential of this collaboration and the impact it will have on relevant stakeholders and the community. Together, we can create meaningful change and drive progress in the industry. Stay tuned for further updates and announcements as we continue this exciting journey with PALADIN. For more information, including PALADIN Playbook and Resource Repository, visit https://lnkd.in/gPk4H8M7. #PatientAdvocacy

Are you attending the World Orphan Drug Congress April 23 - 25th in Boston? If you haven't made a decision yet, here are 3 MORE reasons to attend: 1. Strategic Partnerships and Collaboration: Collaboration is essential for addressing the complex challenges associated with rare diseases and orphan drugs. WODC provides a conducive environment for fostering strategic partnerships and collaborations among industry stakeholders, academic institutions, patient organizations, and government agencies. By working together, attendees can leverage complementary expertise, resources, and networks to accelerate research, improve patient outcomes, and overcome barriers to drug development and access. 2. Opportunity to make a tangible difference in the lives of patients, families and caretakers living with a rare disease and contribute to shaping the future of orphan drug innovation and healthcare policy. 3. Gain access to cutting-edge insights, best practices, and the latest developments in drug discovery, regulatory pathways, patient engagement, market access, and commercialization strategies. These insights can inform decision-making, inspire innovation, and shape future initiatives within the industry. And if you need another reason, I'll be there and I'd love to connect with you! If you would LIKE to attend and work at a biopharma/pharma company - you can get a free pass! Just leave me a comment and tag me! hashtag#raredisease hashtag#rarediseases hashtag#rareaccessactionproject hashtag#WODC hashtag#smallbiopharma

Are you attending the World Orphan Drug Congress April 23 - 25th in Boston? If you haven't made a decision yet, here are 3 MORE reasons to attend: 1. Strategic Partnerships and Collaboration: Collaboration is essential for addressing the complex challenges associated with rare diseases and orphan drugs. WODC provides a conducive environment for fostering strategic partnerships and collaborations among industry stakeholders, academic institutions, patient organizations, and government agencies. By working together, attendees can leverage complementary expertise, resources, and networks to accelerate research, improve patient outcomes, and overcome barriers to drug development and access. 2. Opportunity to make a tangible difference in the lives of patients, families and caretakers living with a rare disease and contribute to shaping the future of orphan drug innovation and healthcare policy. 3. Gain access to cutting-edge insights, best practices, and the latest developments in drug discovery, regulatory pathways, patient engagement, market access, and commercialization strategies. These insights can inform decision-making, inspire innovation, and shape future initiatives within the industry. And if you need another reason, I'll be there and I'd love to connect with you! If you would LIKE to attend and work at a biopharma/pharma company - you can get a free pass! Just leave me a comment and tag me! hashtag#raredisease hashtag#rarediseases hashtag#rareaccessactionproject hashtag#WODC hashtag#smallbiopharma

Thrilled to share our focus on Denmark's healthcare landscape within oncology and hematology at ZEMA Pharma Consulting! 🎯 With +10 years of experience from the Danish healthcare system and the pharmaceutical industry, we understand the ins and outs of the healthcare system. This insight allows us to tailor strategies that resonate deeply with local stakeholders, ensuring effective access to the market through the strategic use of clinical data and crafting convincing health economics approaches together with health economic agencies. We're here to guide you every step of the way. Please feel free to reach out to explore how we can elevate your presence in the Danish market and beyond! 🚀 #ZEMAPharmaConsulting #MedicalAffairs #DanishMarketExpertise

Tomorrow, for Enthereal newsletter subscribers, they'll be hearing about DOI - recent research and regulatory update - which has been in the news due to its upcoming Drug Enforcement Administration hearings not in small part due to the work of Students for Sensible Drug Policy (SSDP), the work of Robert Rush and others (!) As we concluded that overview, we realized we wanted to add something more, so we whipped up the attached graphic, and if you want to have it explained, you don't even have to sign up for the Enthereal newsletter, just go to the one of the latest post on the Enthereal website — it's under "News", and it's there, at this very moment. And if people ask us here, we'll even explain it here. You don't even have to ask in a certain way. Simply ask. But there's more at the website including a break-down of what a phenethylamine even is. And what an amphetamine is in super basic molecular terms. And there's a mini-article on 2Cs. And there's even an initial article on "Illicit Drugs Approved for Medical Use." DOI and DOC are compounds that can readily be made by the technology platform that our founder outlined in 2022, developed in 2023, and we're choosing to hold as secrets until a grad school or other funding gives us the resources and support to develop it for commercialization. (Though we'll explain how it works again in the Enthereal newsletter fairly soon.) It's a bright road ahead — sustainable essential medicines — sustainable emerging therapeutics. We going to make something that'll be a treasure trove for generations to come. DOI is not dead on arrival. Let's support the Students for Sensible Drug Policy (SSDP) and the work of more than 900 research teams to date in learning more about and spreading the news about #DOI.

At Semalytix, we're thrilled to have played a crucial role in developing a groundbreaking paper that explores the optimal practices for ethical #patientengagement and #patientlistening on #socialmedia. Learn more by reading the full paper here: https://lnkd.in/eTNR9xfZ #sociallistening #rwd #rwe #patientcentricity

Short video interview series #ExploreWithJeeva episode 7 of 14 is Live! Pharmaceutical Outsourcing asked Harsha K Rajasimha, our Founder & CEO: “What are some innovative ways to recruit patients, particularly harder-to-reach patients with rare diseases?” He highlights patient recruitment as a global challenge in clinical trials, emphasizing the need for multilingual patient registries to boost diversity. He explains how technology connects biopharma and patient advocacy groups to rare disease communities through these platforms. Watch the other episodes here! 🎧✨   https://lnkd.in/gH4f9hjh #PatientRecruitment #ClinicalTrials #RareDiseaseResearch #PatientRegistry #MultilingualSupport